entertainment -WSS

entertainment

author：fashion 2025-10-01 10:57:22 - browse：82936

It’s no secret that biotech industry funding has fallen from its Covid highs. But with just a few months left in the year, it’s on track to hit lows that predate the pandemic.

New data from Pitchbook and the National Venture Capital Association show that both the number of deals and the amount of money that’s being invested in life science companies are down significantly. So far this year, there have been 1,384 VC deals struck in the field, the lowest figure since 2013. For comparison, there were roughly 2,122 financing deals made last year.

If dealmaking remains consistent for the rest of the year, it would put this year on par with the number of deals made in 2017.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Oprah kicked off a national conversation on obesity. Let's have it

WSS

How to fix cancer clinical trials' diversity problem

Snackable artificial intelligence, expert AI, and the pharma industry

The (many) problems with a new study criticizing cancer screening

What drug price negotiations mean for Medicare Part D

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

A rare thyroid diagnosis led to unexpected, all

focus

entertainment

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

How generative AI is inspiring dreams of a health data revolution

Walensky prepares to leave CDC — and Congress — behind

Food as medicine: Medically tailored meals may get standardized

Medical leaders decry Supreme Court decision on affirmative action

Listen: Biogen's potential pivot, & Illumina's next chapter

Hepatitis C has a cure — but many Americans still lack access to it

Study says nonprofit hospitals fall short in charity care spending

The high cost of giving birth even with insurance

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

focus

Snackable artificial intelligence, expert AI, and the pharma industry

Readout Newsletter: Merck, Vertex, and Viking updates

Abortion pill Supreme Court ruling could impact entire drug industry

NIH nominee Bertagnolli will get October confirmation hearing

Patient advocates debate FDA's accelerated approval process

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

leisure time

focus

Wikipedia

focus